Alector (ALEC) Expected to Announce Quarterly Earnings on Wednesday

Alector (NASDAQ:ALEC) is expected to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Alector to post earnings of ($0.39) per share and revenue of $1.7840 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Alector Trading Up 5.5%

NASDAQ ALEC opened at $2.10 on Tuesday. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.03. Alector has a 12 month low of $0.87 and a 12 month high of $3.40. The firm has a market capitalization of $229.22 million, a P/E ratio of -1.96 and a beta of 0.64.

Insider Activity

In related news, insider Sara Kenkare-Mitra sold 41,687 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $46,689.44. Following the completion of the transaction, the insider directly owned 501,652 shares in the company, valued at approximately $561,850.24. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Neil Lindsay Berkley sold 37,261 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $41,732.32. Following the completion of the transaction, the chief financial officer owned 374,309 shares of the company’s stock, valued at $419,226.08. The trade was a 9.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 196,104 shares of company stock worth $220,064 in the last three months. Corporate insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. bought a new stake in Alector in the 2nd quarter worth $30,000. Virtu Financial LLC purchased a new stake in shares of Alector during the fourth quarter worth about $34,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Alector in the fourth quarter worth about $40,000. Oxford Asset Management LLP bought a new stake in shares of Alector in the fourth quarter worth about $67,000. Finally, Quadrature Capital Ltd purchased a new position in Alector during the 4th quarter valued at about $97,000. 85.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Morgan Stanley reissued an “underweight” rating on shares of Alector in a report on Thursday, January 8th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a research report on Saturday. BTIG Research raised shares of Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.25.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.